CD19 and plasma cell myeloma: Several studies have examine genotypic and phenotypic characteristics associated with the efficacy of anti-CD19 CAR T therapy for B cell malignancies, including ALL, CLL, large B cell lymphoma (LBCL), and multiple myeloma (15, 16, 37, 48, 49).